ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Werewolf Therapeutics Inc

Werewolf Therapeutics Inc (HOWL)

6.75
0.54
(8.70%)
Closed April 27 4:00PM
6.20
-0.55
(-8.15%)
After Hours: 7:51PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
6.20
Bid
6.00
Ask
7.09
Volume
82,150
6.10 Day's Range 6.78
1.5735 52 Week Range 8.1939
Market Cap
Previous Close
6.21
Open
6.22
Last Trade Time
Financial Volume
$ 537,946
VWAP
6.5483
Average Volume (3m)
201,439
Shares Outstanding
42,737,191
Dividend Yield
-
PE Ratio
-7.71
Earnings Per Share (EPS)
-0.87
Revenue
19.94M
Net Profit
-37.37M

About Werewolf Therapeutics Inc

Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Werewolf Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HOWL. The last closing price for Werewolf Therapeutics was $6.21. Over the last year, Werewolf Therapeutics shares have traded in a share price range of $ 1.5735 to $ 8.1939.

Werewolf Therapeutics currently has 42,737,191 shares outstanding. The market capitalization of Werewolf Therapeutics is $288.05 million. Werewolf Therapeutics has a price to earnings ratio (PE ratio) of -7.71.

HOWL Latest News

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE...

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or...

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

 WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models WTX-712, a conditionally activated IL-21...

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

–  Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024  – –  WTX-124 recommended dose for expansion...

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.417.081174438695.796.785.621833296.25237943CS
4-0.34-5.198776758416.546.784.51954415.6914136CS
121.4530.52631578954.758.19394.52014396.20309911CS
263.8158.3333333332.48.19391.95971463.7337832CS
523.84162.7118644072.368.19391.57353282643.63972908CS
156-12.01-65.952773201518.2123.991.392195355.29490687CS
260-12.01-65.952773201518.2123.991.392195355.29490687CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

HOWL Discussion

View Posts
Monksdream Monksdream 4 months ago
HOWL new 52 week high
👍️0
Pt3 Pt3 6 months ago
Yea your gap and trapped make me buy caud instead of this
👍️0
TheFinalCD TheFinalCD 6 months ago
HOWL todays algo patented Gap & Trap on Phase #1 news
👍️0
TheFinalCD TheFinalCD 6 months ago
Werewolf Therapeutics soars 52% premarket after presentsing preliminary monotherapy data from Phase 1/1b clinical trial establishing proof of mechanism for WTX-124$HOWL#AInvest #Ainvest_Wire #trade #source #wallstreet
View more: https://t.co/aTzfU7GqUS pic.twitter.com/rClSWzl2IS— AInvest Wire (@Ainvest_Wire) November 3, 2023
👍️0
TheFinalCD TheFinalCD 6 months ago
$howl flying https://finviz.com/quote.ashx?t=HOWL&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/HOWL
👍️0
tw0122 tw0122 6 months ago
$3 + otw Halloween is here give it a HOWL
👍️0
The Night Stalker The Night Stalker 10 months ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
👍️0
The Night Stalker The Night Stalker 10 months ago
https://stockcharts.com/h-sc/ui?s=howl&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2
👍️0
The Night Stalker The Night Stalker 10 months ago
dip
👍️0
The Night Stalker The Night Stalker 10 months ago
dip
👍️0
The Night Stalker The Night Stalker 10 months ago
watching
👍️0
The Night Stalker The Night Stalker 11 months ago
soon
👍️0
The Night Stalker The Night Stalker 11 months ago
insert dd
👍️0
The Night Stalker The Night Stalker 11 months ago
can be big
👍️0
The Night Stalker The Night Stalker 11 months ago
wow
👍️0
The Night Stalker The Night Stalker 11 months ago
wow
👍️0
The Night Stalker The Night Stalker 11 months ago
hold
👍️0
The Night Stalker The Night Stalker 11 months ago
slow
👍️0
The Night Stalker The Night Stalker 11 months ago
slow
👍️0
The Night Stalker The Night Stalker 11 months ago
agreed
👍️0
The Night Stalker The Night Stalker 11 months ago
like thiks
👍️0
The Night Stalker The Night Stalker 11 months ago
off radar
👍️0
The Night Stalker The Night Stalker 11 months ago
catchy name
👍️0
The Night Stalker The Night Stalker 11 months ago
catchy name
👍️0
surf1944 surf1944 12 months ago
https://stockcharts.com/h-sc/ui?s=howl&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/howl/opinion
👍️0
Mr. Zen Mr. Zen 1 year ago
Watch list addition, this has the potential to run, just waiting for all the pieces of the puzzle to come together.

“These promising preclinical data add to a growing body of evidence demonstrating the potential of WTX-330 to drive targeted anti-tumor immune responses selectively in the tumor microenvironment (TME),” said Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer of Werewolf Therapeutics. “This morning, in our Third Quarter 2022 release, we announced that the FDA has granted clearance of the investigational new drug (IND) application for WTX-330. We are excited to advance WTX-330 into the clinic and to continue developing a pipeline of novel proinflammatory cytokine therapies that have the potential to change the lives of cancer patients.”
👍️0
makinezmoney makinezmoney 1 year ago
$HOWL: Hey thanks....... now 3.20.

Only getting better right ??


Enjoy those profits.





GO $HOWL
👍️0
Makk1 Makk1 1 year ago
Good call here, looking very good
👍️0
makinezmoney makinezmoney 1 year ago
$HOWL: Looks like its turning...... now 2.25

Let see if volume pushes it up.


The setup is nice


GO $HOWL
👍️0
bobbo5 bobbo5 1 year ago
I agree and it looks like share price has been moving up this past week
👍️0
dia76ca dia76ca 1 year ago
Very interesting company. I like it's chances.
👍️0

Your Recent History

Delayed Upgrade Clock